PURPOSE: A prior paper from this study demonstrated that patient report of receiving medication instructions from health care professionals is associated with reduced risk of warfarin-related bleeding hospitalizations. The objective of this analysis was to describe the hospitalization costs due to warfarin-related bleeding events in older community-dwelling adults and to estimate the hospitalization costs avoided due to the receipt of medication instruction from different sources. METHODS: We estimated the expected hospitalization costs associated with four instruction sources based on the respective incidence rate of observed hospitalizations and mean hospitalization cost for warfarin-related bleeding episodes from a prospective cohort study of beneficiaries of the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE). We estimated hospitalization costs avoided due to each instruction source compared to no instructions using the payer's perspective. We conducted probabilistic sensitivity analysis to account for uncertainty in our parameters. RESULTS: One hundred twenty-six warfarin-related bleeding hospitalizations occurred during the observation period with a mean cost of $10,819 (SD: $11,536). The mean expected hospitalization cost from a warfarin-related bleeding hospitalization without instruction was $835 per year per person. Hospitalization costs avoided with instruction from a health care professional ranged from $443 to $481 per year per person. CONCLUSIONS: The costs per hospitalization associated with warfarin-related bleeding events are substantial. Instructions for warfarin management from a health care professional may reduce the number of warfarin-related bleeding hospitalizations and associated costs. Investments in interventions to improve communication regarding warfarin management may be justified economically based on the potential cost savings estimated in this study. (c) 2010 John Wiley & Sons, Ltd.
PURPOSE: A prior paper from this study demonstrated that patient report of receiving medication instructions from health care professionals is associated with reduced risk of warfarin-related bleeding hospitalizations. The objective of this analysis was to describe the hospitalization costs due to warfarin-related bleeding events in older community-dwelling adults and to estimate the hospitalization costs avoided due to the receipt of medication instruction from different sources. METHODS: We estimated the expected hospitalization costs associated with four instruction sources based on the respective incidence rate of observed hospitalizations and mean hospitalization cost for warfarin-related bleeding episodes from a prospective cohort study of beneficiaries of the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE). We estimated hospitalization costs avoided due to each instruction source compared to no instructions using the payer's perspective. We conducted probabilistic sensitivity analysis to account for uncertainty in our parameters. RESULTS: One hundred twenty-six warfarin-related bleeding hospitalizations occurred during the observation period with a mean cost of $10,819 (SD: $11,536). The mean expected hospitalization cost from a warfarin-related bleeding hospitalization without instruction was $835 per year per person. Hospitalization costs avoided with instruction from a health care professional ranged from $443 to $481 per year per person. CONCLUSIONS: The costs per hospitalization associated with warfarin-related bleeding events are substantial. Instructions for warfarin management from a health care professional may reduce the number of warfarin-related bleeding hospitalizations and associated costs. Investments in interventions to improve communication regarding warfarin management may be justified economically based on the potential cost savings estimated in this study. (c) 2010 John Wiley & Sons, Ltd.
Authors: J S Schildcrout; J C Denny; E Bowton; W Gregg; J M Pulley; M A Basford; J D Cowan; H Xu; A H Ramirez; D C Crawford; M D Ritchie; J F Peterson; D R Masys; R A Wilke; D M Roden Journal: Clin Pharmacol Ther Date: 2012-06-27 Impact factor: 6.875
Authors: Kelly Comerford Wormer; Ayesha A Jangda; Farah A El Sayed; Katherine I Stewart; Sunni L Mumford; James H Segars Journal: Eur J Obstet Gynecol Reprod Biol Date: 2018-03-19 Impact factor: 2.435
Authors: C Michael Gibson; Duane S Pinto; Gerald Chi; Douglas Arbetter; Megan Yee; Roxana Mehran; Christoph Bode; Jonathan Halperin; Freek W A Verheugt; Peter Wildgoose; Paul Burton; Martin van Eickels; Serge Korjian; Yazan Daaboul; Purva Jain; Gregory Y H Lip; Marc Cohen; Eric D Peterson; Keith A A Fox Journal: Circulation Date: 2016-11-14 Impact factor: 29.690
Authors: Leiliane Marcatto; Bruno Boer; Luciana Sacilotto; Natália Olivetti; Francisco Carlos Costa Darrieux; Maurício Ibrahim Scanavacca; Alexandre Costa Pereira; Paulo Caleb Junior Lima Santos Journal: J Thromb Thrombolysis Date: 2020-09-24 Impact factor: 2.300
Authors: Brian Godman; Alexander E Finlayson; Parneet K Cheema; Eva Zebedin-Brandl; Inaki Gutiérrez-Ibarluzea; Jan Jones; Rickard E Malmström; Elina Asola; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Bucsics; Stephen Campbell; Eduardo Diogene; Alessandra Ferrario; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Katharine Harris; Alan Haycox; Harald Herholz; Krystyna Hviding; Saira Jan; Marija Kalaba; Christina Kvalheim; Ott Laius; Sven-Ake Lööv; Kamila Malinowska; Andrew Martin; Laura McCullagh; Fredrik Nilsson; Ken Paterson; Ulrich Schwabe; Gisbert Selke; Catherine Sermet; Steven Simoens; Dominik Tomek; Vera Vlahovic-Palcevski; Luka Voncina; Magdalena Wladysiuk; Menno van Woerkom; Durhane Wong-Rieger; Corrine Zara; Raghib Ali; Lars L Gustafsson Journal: BMC Med Date: 2013-08-13 Impact factor: 8.775